HRV Pharma to acquire German firm Phatebo
The acquisition will take it beyond active pharmaceutical ingredients into finished formulations and give it a licensed operating business in Germany.
Account subscription benefits alongside Premium Stories, Editorials, Opinions and more.
Unlock these with Subscription
The View From India Looking at World Affairs from the Indian perspective.
First Day First Show News and reviews from the world of cinema and streaming.
Today's Cache Your download of the top 5 technology stories of the day.
Science For All The weekly newsletter from science writers takes the jargon out of science and puts the fun in!
Data Point Decoding the headlines with facts, figures, and numbers
THEdge At the cutting edge of education and careers
Health Matters Ramya Kannan writes to you on getting to good health, and staying there
Gender Agenda Stories from beyond the binary.
The Hindu On Books Books of the week, reviews, excerpts, new titles and features.
Published - November 03, 2026 08:14 pm IST - HYDERABAD
HRV Pharma, a virtual pharmaceutical company headquartered in Hyderabad, is acquiring Phatebo GmbH, a licensed pharmaceutical wholesaler in Germany specialising in clinical trial supply.
The acquisition will take it beyond active pharmaceutical ingredients into finished formulations and give it a licensed operating business in Germany, HRV said on Tuesday.
It, however, did not disclose the terms of transaction.
Phatebo had revenues of around ₹350 crore in 2025, HRV said, announcing the signing of definitive agreements to acquire 100% in Phatebo from ZeroStack Corp.
Founded in 2015, the German firm sources investigational, comparator and ancillary medicines, including innovative branded therapies, for global pharmaceutical companies and clinical research organisations.
It operates quality systems built for good distribution practice, and it also trades in pharmaceuticals and medical devices across Europe and international markets, the company said.
Phatebo will continue to operate under its own name from Hilzingen, Germany, led by Managing Director Martin Lisker, with its existing team and customer agreements in place.
“Bringing them into the HRV family gives us our first finished formulations business, alongside the API portfolio we have built since 2015,” said Hari Kiran Chereddi, founder, MD and CEO of HRV Pharma.
business (general) / pharmaceutical / medicine / merger, acquisition and takeover / foreign investment / international (foreign) trade
Terms & conditions | Institutional Subscriber
Comments have to be in English, and in full sentences.
They cannot be abusive or personal.
Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform.
If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles.
If you do not have an account please register and login to post comments.
Users can access their older comments by logging into their accounts on Vuukle.
Full detailed coverage is shown on the council website above. Source attribution: The Hindu – Business.
Back to all council news
